Understanding the Updated Final Rule on Research Misconduct: Key Changes and Institutional Impacts
The first substantial update in decades to the PHS research misconduct rule — key changes and what they mean for institutions.
Read more →Regulatory updates, guidance summaries and news from the HRP team.
The first substantial update in decades to the PHS research misconduct rule — key changes and what they mean for institutions.
Read more →Where artificial intelligence delivers genuine efficiency in clinical research, and where it creates new compliance questions for IRBs.
Read more →The FDA Regulations cited in this table are primarily from 21 CFR 50 and 56 as these regulations refer to human subject protection and institutional review boards (IRBs). The proposed FDA changes cited in this table are from FDA proposed…
Read more →Exception from Informed Consent in emergency research: the regulatory basis, community consultation obligations and the practical demands on an IRB.
Read more →Comparison of Common Rule_FDA_Revised FDA_May 2024 The FDA Regulations cited in this table are primarily from 21 CFR 50 and 56 as these regulations refer to human subject protection and institutional review boards (IRBs). The proposed FDAchanges cited in this…
Read more →FDA Final Rule – Waiver or Alteration of Informed Consent for Minimal Risk Clinical Investigations Fast Facts On December 21, 2023, the Food and Drug Administration (FDA) published a Final Rule “Institutional Review Board Waiver or Alteration of Informed Consent…
Read more →HRP recently had a very helpful email dialogue with OHRP regarding the cooperative review (single IRB) provisions in the revised Common Rule. OHRP has graciously provided permission for us to disseminate the information they provided and have asked that we…
Read more →We’re all eagerly watching the evolving ethical and regulatory landscape in research, with updated guidance from several agencies and organizations, the unknown implications of AI and the increasing dependency on technology to conduct our trials. For those who have been…
Read more →HRP recently engaged in extensive correspondence with the FDA regarding the following statements that appeared in one of the later iteration’s of the FDA’s guidance document “Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency”: Where…
Read more →HRP recently sought clarification from NIH and OHRP regarding the process for organizations to request exceptions from the revised Common Rule requirement for single IRB for cooperative research. While NIH was previously able to grant exceptions from its own single…
Read more →